Enigmatic receptors

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 201-203

  Brasili, Livio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

1 Phenyl 3 aminotetralines (PATs); 2 BFI; Benazoline; BU 224; BU 239; Imidazoline (I) receptors; Metrazoline; NE 100; PMS 812; Sigma ( ) receptors; Spipethiane; Tracizoline

Indexed keywords

1 (2,4 DICHLOROBENZYL) 2 (2 IMIDAZOLIN 2 YL) 4 METHYLPIPERAZINE; 2 (2 IMIDAZOLIN 2 YL)BENZZOFURAN; 2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 2 (2 IMIDAZOLIN 2 YL)QUINOXALINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 3 AMINO 1 PHENYLTETRALIN DERIVATIVE; AGMATINE; IMIDAZOLINE RECEPTOR; METIZOLINE; METRAZOLINE; N ALLYLNORMETAZOCINE; PENTAZOCINE; RECEPTOR; SIGMA OPIATE RECEPTOR; SPIPETHIANE; TRACIZOLINE; UNCLASSIFIED DRUG;

CELL MEMBRANE; CONFERENCE PAPER; DRUG DESIGN; HISTOCHEMISTRY; LIGAND BINDING; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, DRUG; RECEPTORS, SIGMA;

EID: 0034112188     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00033-3     Document Type: Conference Paper

References (26)

1. Bousquet P., Feldman J., Schwartz J. Central cardiovascular effects of the α-adrenergic drugs. Differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230:1984;232-236.
2. 2 sites. Ann. N.Y. Acad. Sci. 763:1995;153-156.
3. 1-imidazoline receptor. Definition, characterization, distribution, and trans-membrane signaling. Ann. N.Y. Acad. Sci. 763:1995;22-42.
4. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J. Hypertens. 15(1):1997;S9-S23. Suppl.
5. 1-binding site. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8072-8077.
6. Itzhak Y., Stein I. Regulation of sigma receptors and responsiveness to guanine nucleotides following repeated exposure to haloperidol: further evidence for multiple sigma binding sites. Brain Res. 566:1991;166-172.
7. Kekuda R., Prasad P.D., Fei Y.J., Leibach F.H., Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 229:1996;553-558.
8. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 263:1994;966-969.
9. Martin W.R., Eades C.G., Thomson J.A., Happler R.E., Gilbert P.E. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532.
10. Michel M.C., Ernsberger P. Keeping an eye on the I site: imidazoline preferring receptors. Trends Pharmacol. Sci. 13:1992;369-370.
11. Milligan C.M., MacKinnon A.C. Imidazoline receptor ligands. Drugs New Perspect. 10:1997;74-84.
12. Moebius F.F., Striessnig J., Glossman H. The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 18:1997;67-70.
13. Molderings G.J. Imidazoline receptors: basic knowledge, recent advances and future prospects for therapy and diagnosis. Drug Future. 22:1997;757-772.
14. 2-imidazoline binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1991;507-516.
15. Monnet F.P., Debonnel G., Bergeron R., Gronier B., de Montigny C. The effects of sigma ligands and neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurons are differentially affected by pertussin toxin. Br. J. Pharmacol. 112:1994;709-715.
16. Nakazato A., Ohta K., Sekiguchi Y., Okuyama S., Chaki S., Kawashima Y., Hatayama K. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs. J. Med. Chem. 42:1999;1076-1087.
17. Pigini M., Bousquet P., Carotti A., Dontenwill M., Giannella M., Moriconi R., Piergentili A., Quaglia W., Tayebati S.K., Brasili L. Imidazoline receptor: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem. 5:1997;843-856.
18. 2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models. Bioorg. Med. Chem. 6:1998;2245-2260.
19. 3H ]-p-aminoclonidine to alpha 2-adrenoceptor state plus a non-adrenergic sites on human platelet plasma membranes Biochem. Pharmacol. 42:1991;569-584.
20. 1 ligand. J. Med. Chem. 41:1998;1557-1560.
21. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., Taylor D.P. A proposal for the classification of sigma binding sites. Trends. Pharmacol. Sci. 13:1992;85-86.
22. Regunathan S., Reis D.J. Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol. 36:1996;511-544.
23. Rondu F., LE Bihan G., Wang X., Lamouri A., Touboul E., Dive G., Bellahsene T., Pfeiffer B., Renard P., Guardiola-Lamaitre B., Manechez D., Penicaud L., Ktorza A., Godfroid J.-J. Design and synthesis of imidazoline derivatives active on glucose homeostasis in rat model of type II diabetes: 1. Synthesis and biological activities of N-benzyl-N′-(arylalkyl)-2-(4′,5′-dihydro-1′H-imidazol- 2′-yl)piperazines. J. Med. Chem. 40:1997;3793-3803.
24. 2-imidazoline binding sites on monoamino oxidases. J. Biol. Chem. 270:1995;681-688.
25. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 55:1995;408-413.
26. Wyrick S.D., Booth R. Progress in sigma receptor research. Drugs Future. 20:1995;1033-1044.